166 related articles for article (PubMed ID: 36382478)
21. [TDP-43 proteinopathies - from frontotemporal lobar degeneration to inclusion body myositis].
Kierdaszuk B; Berdyński M; Zekanowski C; Kamińska A
Neurol Neurochir Pol; 2012; 46(4):384-91. PubMed ID: 23023438
[TBL] [Abstract][Full Text] [Related]
22. TDP-43 pathology occurs infrequently in multiple system atrophy.
Geser F; Malunda JA; Hurtig HI; Duda JE; Wenning GK; Gilman S; Low PA; Lee VM; Trojanowski JQ
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):358-65. PubMed ID: 20942898
[TBL] [Abstract][Full Text] [Related]
23. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.
Uryu K; Nakashima-Yasuda H; Forman MS; Kwong LK; Clark CM; Grossman M; Miller BL; Kretzschmar HA; Lee VM; Trojanowski JQ; Neumann M
J Neuropathol Exp Neurol; 2008 Jun; 67(6):555-64. PubMed ID: 18520774
[TBL] [Abstract][Full Text] [Related]
24. The influence of Aβ-dependent and independent pathways on TDP-43 proteinopathy in Alzheimer's disease: a possible connection to LATE-NC.
Jamerlan A; An SSA
Neurobiol Aging; 2020 Nov; 95():161-167. PubMed ID: 32814257
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for diseases with TDP-43 pathology.
Steinacker P; Barschke P; Otto M
Mol Cell Neurosci; 2019 Jun; 97():43-59. PubMed ID: 30399416
[TBL] [Abstract][Full Text] [Related]
26. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
Geser F; Lee VM; Trojanowski JQ
Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
[TBL] [Abstract][Full Text] [Related]
27. FTLD-TDP and progressive supranuclear palsy in comorbidity-a report of two cases with different clinical presentations.
Storey K; Johanidesová S; Matěj R; Keller J; Rohan Z; Rusina R
Neurocase; 2017 Feb; 23(1):5-11. PubMed ID: 27915581
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43.
King A; Maekawa S; Bodi I; Troakes C; Al-Sarraj S
Neuropathology; 2011 Jun; 31(3):239-49. PubMed ID: 21118398
[TBL] [Abstract][Full Text] [Related]
29. Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting.
Armstrong RA; Hamilton RL; Mackenzie IR; Hedreen J; Cairns NJ
Neuropathol Appl Neurobiol; 2013 Jun; 39(4):335-47. PubMed ID: 22804696
[TBL] [Abstract][Full Text] [Related]
30. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy.
Chornenkyy Y; Fardo DW; Nelson PT
Lab Invest; 2019 Jul; 99(7):993-1007. PubMed ID: 30742063
[TBL] [Abstract][Full Text] [Related]
31. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
32. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases.
Arnold SE; Toledo JB; Appleby DH; Xie SX; Wang LS; Baek Y; Wolk DA; Lee EB; Miller BL; Lee VM; Trojanowski JQ
J Comp Neurol; 2013 Dec; 521(18):4339-55. PubMed ID: 23881776
[TBL] [Abstract][Full Text] [Related]
33. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R
Curr Opin Neurol; 2008 Dec; 21(6):693-700. PubMed ID: 18989115
[TBL] [Abstract][Full Text] [Related]
34. Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies.
Kokoulina P; Rohn TT
Neurodegener Dis; 2010; 7(4):243-50. PubMed ID: 20551689
[TBL] [Abstract][Full Text] [Related]
35. Revisiting the relevance of Hirano bodies in neurodegenerative diseases.
Yoshida K; Forrest SL; Ichimata S; Tanaka H; Kon T; Tartaglia MC; Tator CH; Lang AE; Nishida N; Kovacs GG
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12978. PubMed ID: 38634242
[TBL] [Abstract][Full Text] [Related]
36. TDP-43 Pathology in Alzheimer's Disease.
Meneses A; Koga S; O'Leary J; Dickson DW; Bu G; Zhao N
Mol Neurodegener; 2021 Dec; 16(1):84. PubMed ID: 34930382
[TBL] [Abstract][Full Text] [Related]
37. Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: effects of genetic, demographic and neuropathological variables.
Armstrong RA
Folia Neuropathol; 2016; 54(2):137-48. PubMed ID: 27543771
[TBL] [Abstract][Full Text] [Related]
38. Cortical degeneration in frontotemporal lobar degeneration with TDP-43 proteinopathy caused by progranulin gene mutation.
Armstrong RA
Int J Neurosci; 2014 Dec; 124(12):894-903. PubMed ID: 24494724
[TBL] [Abstract][Full Text] [Related]
39. Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis.
Boeve BF
Alzheimer Dis Assoc Disord; 2007; 21(4):S31-8. PubMed ID: 18090421
[TBL] [Abstract][Full Text] [Related]
40. Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP).
Armstrong RA; Cairns NJ
Neurol Sci; 2011 Aug; 32(4):653-9. PubMed ID: 21647631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
